Dual-Target CAR-T therapy takes on tough leukemia
NCT ID NCT07198867
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. A-CAR028 is a type of immune cell therapy (CAR-T) that is designed to recognize and attack leukemia cells by targeting two specific proteins. The study will enroll 20 adults aged 18 to 75 and will primarily look at safety and how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A-CAR028 (a type of CAR-T cell therapy that targets two proteins, CD33 and CLL-1, on leukemia cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat acute myeloid leukemia, potentially leading to remission.
What could go wrong
This is a very early (Phase 1) and small trial (20 people), so it may not work or could have serious side effects. CAR-T therapy can cause severe immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••